UBS/CALL/MODERNA/140.001/0.1/21.03.25 | Market Closed - Swiss Exchange 08:50:00 04/06/2024 pm IST | ||
| 2.81 CHF | -11.08% |
|
| Current month | -8.17% | ||
| 1 month | +60.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 2.81 | -11.08% |
| 03/24/03 | 3.16 | +3.27% |
| 31/24/31 | 3.06 | +6.25% |
| 30/24/30 | 2.88 | -0.69% |
| 29/24/29 | 2.9 | -16.67% |
Delayed Quote Swiss Exchange
Last update June 04, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| TMRN3U | |
| ISIN | CH1330871968 |
| Date issued | 18/03/2024 |
| Strike | 140 $ |
| Maturity | 21/03/2025 (290 Days) |
| Parity | 10 : 1 |
| Emission price | 1.1 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 4.44 CHF |
|---|---|
| Lowest since issue | 0.98 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.32% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.3
USD
Average target price
142.8
USD
Spread / Average Target
-1.74%
- Stock Market
- Warrants
- TMRN3U Warrant
